Insider Trading Activity For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
John Maraganore , CEO of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reportedly Sold 49,456 shares of the company’s stock at an average price of 79.45 for a total transaction amount of $3,929,279.20 SEC Form
Insider Trading History For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Analyst Ratings History For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- On 10/30/2017 FBR & Co Initiated Coverage of rating Buy to Buy with a price target of $150.00
- On 11/9/2017 JPMorgan Chase & Co. Upgraded rating Neutral to Overweight
- On 3/13/2018 Credit Suisse Group Boost Price Target of rating Outperform to Outperform with a price target of $151.00 to $154.00
- On 8/6/2018 Jefferies Financial Group Reiterated Rating Buy with a price target of $149.00
- On 8/13/2018 B. Riley Boost Price Target of rating Buy to Buy with a price target of $210.00 to $230.00
- On 8/28/2018 JMP Securities Set Price Target of rating Buy with a price target of $198.00
- On 12/17/2018 Guggenheim Initiated Coverage of rating Buy with a price target of $105.00
Recent Trading Activity for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Shares of Alnylam Pharmaceuticals, Inc. closed the previous trading session at with 80.39 shares trading hands.